Trinity Biotech
TRIB
26 hedge funds and large institutions have $15.9M invested in Trinity Biotech in 2020 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 6 closing their positions.
2,442% more call options, than puts
Call options by funds: $661K | Put options by funds: $26K
67% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 6
64% more capital invested
Capital invested by funds: $9.66M → $15.9M (+$6.21M)
18% more funds holding
Funds holding: 22 → 26 (+4)
0.01% less ownership
Funds ownership: 0.06% → 0.05% (-0.01%)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$1.07M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$261K |
| 3 |
Morgan Stanley
New York
|
+$204K |
| 4 |
HAIM
Hunter Associates Investment Management
Pittsburgh,
Pennsylvania
|
+$163K |
| 5 |
Goldman Sachs
New York
|
+$90.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PIM
Paradice Investment Management
Denver,
Colorado
|
-$1.7M |
| 2 |
SCM
Stonehill Capital Management
New York
|
-$908K |
| 3 |
ICM
Invenomic Capital Management
Boston,
Massachusetts
|
-$406K |
| 4 |
FM
Fondren Management
Houston,
Texas
|
-$253K |
| 5 |
Millennium Management
New York
|
-$120K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
FM
26
Fondren Management
Houston,
Texas
| – | -$253K | -1,533 | Closed |
|
|
27
Millennium Management
New York
| – | -$120K | -727 | Closed |
|
28
UBS Group
Zurich,
Switzerland
| – | -$17K | -101 | Closed |
|
|
CCM
29
Covington Capital Management
Los Angeles,
California
| – | -$2K | -14 | Closed |
|
30
Simplex Trading
Chicago,
Illinois
| – | +$457 | +2 | New |
|
TRIB Hedge Fund Activity: Q2 2020 in Review
26 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Trinity Biotech (TRIB) for Q2 2020, worth a combined $15.9M — up 64% from $9.66M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new TRIB positions and 6 closed out — a net gain of 4 holders — while 4 added to existing stakes and 5 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $1.07M. The largest seller was Paradice Investment Management, exiting entirely with an estimated $1.7M sold.
- 26 institutional investors held Trinity Biotech (TRIB) as of Q2 2020, up from 22 in Q1 2020.
- Funds reported $15.9M of Trinity Biotech stock for Q2 2020, up 64% quarter-over-quarter.
- 10 funds opened new Trinity Biotech positions in Q2 2020 and 6 closed out, a net change of +4 holders.
- The largest Trinity Biotech buyer in Q2 2020 was Renaissance Technologies, an estimated $1.07M added.
- The largest Trinity Biotech seller in Q2 2020 was Paradice Investment Management, an estimated $1.7M sold.
Based on aggregated 13F filings for Q2 2020.